Probiotics differently affect gut-associated lymphoid tissue indolamine-2, 3-dioxygenase mRNA and cerebrospinal fluid neopterin levels in antiretroviral-treated HIV-1 infected patients: A pilot study

International Journal of Molecular Sciences

Volumn 17, Issue 10, 2016, Pages

  Scagnolari, Carolina ^a,b   Scheri, Giuseppe Corano ^b   Selvaggi, Carla ^b   Schietroma, Ivan ^b   Fard, Saeid Najafi ^b   Mastrangelo, Andrea ^b   Giustini, Noemi ^b   Serafino, Sara ^b   Pinacchio, Claudia ^a   Pavone, Paolo ^b   Fanello, Gianfranco ^c   Ceccarelli, Giancarlo ^b   Vullo, Vincenzo ^b   D’Ettorre, Gabriella ^b  

^a Pasteur Institute   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

CNS; HAND; HIV 1; IDO; Neopterin; Tryptophan

Indexed keywords

INDOLEAMINE 2,3 DIOXYGENASE; MESSENGER RNA; NEOPTERIN; PROBIOTIC AGENT;

ADJUVANT THERAPY; ADULT; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; COLONOSCOPY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; INTESTINE LYMPHATIC TISSUE; LONGITUDINAL STUDY; MALE; PILOT STUDY; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION;

EID: 84989344899     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms17101639     Document Type: Article

References (47)

1. Routy, J.P.; Mehraj, V.; Vyboh, K.; Cao, W.; Kema, I.; Jenabian, M.A. Clinical relevance of kynurenine pathway in HIV/AIDS: An immune checkpoint at the crossroads of metabolism and inflammation. AIDS Rev. 2015, 17, 96–106.
2. Vyboh, K.; Jenabian, M.A.; Mehraj, V.; Routy, J.P. HIV and the gut microbiota, partners in crime: Breaking the vicious cycle to unearth new therapeutic targets. J. Immunol. Res. 2015, 2015, 614127.
3. Carabotti, M.; Scirocco, A.; Maselli, M.A.; Severi, C. The gut-brain axis: Interactions between enteric microbiota, central and enteric nervous systems. Ann. Gastroenterol. 2015, 28, 203–209.
4. Montiel-Castro, A.J.; González-Cervantes, R.M.; Bravo-Ruiseco, G.; Pacheco-López, G. The microbiota-gu-brain axis: Neurobehavioral correlates, health and sociality. Front. Integr. Neurosci. 2013, 7, 70.
5. Atarashi, K.; Tanoue, T.; Shima, T.; Imaoka, A.; Kuwahara, T.; Momose, Y.; Cheng, G.; Yamasaki, S.; Saito, T.; Ohba, Y.; et al. Induction of colonic regulatory T cells by indigenous Clostridium species. Science 2011, 331, 337–341.
6. Favre, D.; Mold, J.; Hunt, P.W.; Kanwar, B.; Loke, P.; Seu, L.; Barbour, J.D.; Lowe, M.M.; Jayawardene, A.; Aweeka, F.; et al. Tryptophan catabolism by indoleamine 2, 3-dioxygenase 1 alters the balance of TH17 to regulatory T cells in HIV disease. Sci. Transl. Med. 2010, 2, 32–36.
7. Serrano-Villar, S.; Rojo, D.; Martínez-Martínez, M.; Deusch, S.; Vázquez-Castellanos, J.F.; Sainz, T.; Vera, M.; Moreno, S.; Estrada, V.; Gosalbes, M.J.; et al. HIV infection results in metabolic alterations in the gut microbiota different from those induced by other diseases. Sci. Rep. 2016, 6, 26192.
8. Boasso, A. Wounding the immune system with its own blade: HIV-induced tryptophan catabolism and pathogenesis. Curr. Med. Chem. 2011, 18, 2247–2256.
9. Boasso, A.; Shearer, G.M.; Chougnet, C. Immune dysregulation in human immunodeficiency virus infection: Know it, fix it, prevent it? J. Intern. Med. 2009, 265, 78–96.
10. Heyes, M.P.; Brew, B.J.; Martin, A.; Price, R.W.; Salazar, A.M.; Sidtis, J.J.; Yergey, J.A.; Mouradian, M.M.; Sadler, A.E.; Keilp, J.; et al. Quinolinic acid in cerebrospinal fluid and serum in HIV-1 infection: Relationship to clinical and neurological status. Ann. Neurol. 1991, 29, 202–209.
11. Heyes, M.P.; Ellis, R.J.; Ryan, L.; Childers, M.E.; Grant, I.; Wolfson, T.; Archibald, S.; Jernigan, T.L.; HNRC Group; HIV Neurobehavioral Research Center. Elevated cerebrospinal fluid quinolinic acid levels are associated with region-specific cerebral volume loss in HIV infection. Brain 2001, 124, 1033–1042.
12. Valle, M.; Price, R.W.; Nilsson, A.; Heyes, M.; Verotta, D. CSF quinolinic acid levels are determined by local HIV infection: Cross-sectional analysis and modelling of dynamics following antiretroviral therapy. Brain 2004, 127, 1047–1060.
13. O’Mahony, S.M.; Clarke, G.; Borre, Y.E.; Dinan, T.G.; Cryan, J.F. Serotonin, tryptophan metabolism and the brain-gut-microbiome axis. Behav. Brain Res. 2015, 277, 32–48.
14. Boasso, A.; Herbeuval, J.P.; Hardy, A.W.; Anderson, S.A.; Dolan, M.J.; Fuchs, D.; Shearer, G.M. HIV inhibits CD4+ T-cell proliferation by inducing indoleamine 2, 3-dioxygenase in plasmacytoid dendritic cells. Blood 2007, 109, 3351–3359.
15. Reeves, R.K.; Rajakumar, P.A.; Evans, T.I.; Connole, M.; Gillis, J.; Wong, F.E.; Kuzmichev, Y.V.; Carville, A.; Johnson, R.P. Gut inflammation and indoleamine deoxygenase inhibit IL-17 production and promote cytotoxic potential in NKp44+ mucosal NK cells during SIV infection. Blood 2011, 11, 3321–3330.
16. Vujkovic-Cvijin, I.; Dunham, R.M.; Iwai, S.; Maher, M.C.; Albright, R.G.; Broadhurst, M.J.; Hernandez, R.D.; Lederman, M.M.; Huang, Y.; Somsouk, M.; et al. Dysbiosis of the gut microbiota is associated with HIV disease progression and tryptophan catabolism. Sci. Transl. Med. 2013, 5, 193ra91.
17. Griffin, D.E.; McArthur, J.C.; Cornblath, D.R. Neopterin and interferon-gamma in serum and cerebrospinal fluid of patients with HIV-associated neurologic disease. Neurology 1991, 41, 69–74.
18. Sönnerborg, A.B.; von Stedingk, L.V.; Hansson, L.O.; Strannegård, O.O. Elevated neopterin and β2-microglobulin levels in blood and cerebrospinal fluid occur early in HIV-1 infection. AIDS 1989, 3, 277–283.
19. Fuchs, D.; Chiodi, F.; Albert, J.; Asjö, B.; Hagberg, L.; Hausen, A.; Norkrans, G.; Reibnegger, G.; Werner, E.R.; Wachter, H. Neopterin concentrations in cerebrospinal fluid and serum of individuals infected with HIV-1. AIDS 1989, 3, 285–288.
20. Eden, A.; Price, R.W.; Spudich, S.; Fuchs, D.; Hagberg, L.; Gisslén, M. Immune activation of the central nervous system is still present after >4 years of effective HAART. J. Infect. Dis. 2007, 196, 1779–1783.
21. Yilmaz, A.; Yiannoutsos, C.T.; Fuchs, D.; Price, R.W.; Crozier, K.; Hagberg, L.; Spudich, S.; Gisslén, M. Cerebrospinal fluid neopterin decay characteristics after initiation of antiretroviral therapy. J. Neuroinflamm. 2013, 10, 10–62.
22. Hagberg, L.; Cinque, P.; Gisslen, M.; Brew, B.J.; Spudich, S.; Bestetti, A. Cerebrospinal fluid neopterin: An informative biomarker of central nervous system immune activation in HIV-1 infection. AIDS Res. Ther. 2010, 7, 15.
23. Calcagno, A.; Atzori, C.; Romito, A.; Vai, D.; Audagnotto, S.; Stella, M.L.; Montrucchio, C.; Imperiale, D.; di Perri, G.; Bonora, S. Blood brain barrier impairment is associated with cerebrospinal fluid markers of neuronal damage in HIV-positive patients. J. Neurovirol. 2016, 22, 88–92.
24. Edén, A.; Marcotte, T.D.; Heaton, R.K.; Nilsson, S.; Zetterberg, H.; Fuchs, D.; Franklin, D.; Price, R.W.; Grant, I.; Letendre, S.L.; et al. Increased intrathecal immune activation in virally suppressed HIV-1 infected patients with neurocognitive impairment. PLoS ONE 2016, 11, e0157160.
25. Andersson, L.M.; Hagbwerg, L.; Fuchs, D.; Svennerholm, B.; Gisslen, M. Increased blood brain-barrier permeability in neuroasymptomatic HIV-1-infected individuals-correlation with cerebrospinal fluid HIV-1 RNA and neopterin levels. J. Neurovirol. 2001, 7, 542–547.
26. Schroecksnadel, K.; Sarcletti, M.; Winkler, C.; Mumelter, B.; Weiss, G.; Fuchs, D.; Kemmler, G.; Zangerle, R. Quality of life and immune activation in patients with HIV-infection. Brain Behav. Immun. 2008, 22, 881–889.
27. Huber, C.; Batchelor, J.R.; Fuchs, D.; Hausen, A.; Lang, A.; Niederwieser, D.; Reibnegger, G.; Swetly, P.; Troppmair, J.; Wachter, H. Immune response-associated production of neopterin. Release from macrophages primarily under control of interferon-. J. Exp. Med. 1984, 160, 310–316.
28. Borre, Y.E.; Moloney, R.D.; Clarke, G.; Dinan, T.G.; Cryan, J.F. The impact of microbiota on brain and behavior: Mechanisms & therapeutic potential. Adv. Exp. Med. Biol. 2014, 817, 373–403.
29. Cryan, J.F.; Dinan, T.G. Mind-altering microorganisms: The impact of the gut microbiota on brain and behaviour. Nat. Rev. Neurosci. 2012, 13, 701–712.
30. Mayer, E.A. Gut feelings: The emerging biology of gut–brain communication. Nat. Rev. Neurosci. 2011, 12, 453–466.
31. Frazier, T.H.; DiBaise, J.K.; McClain, C.J. Gut microbiota, intestinal permeability, obesity-induced inflammation, and liver injury. J. Parenter. Enter. Nutr. 2011, 35, 14S–20S.
32. Camilleri, M.; Lasch, K.; Zhou, W. Irritable bowel syndrome: Methods, mechanisms, and pathophysiology. The confluence of increased permeability, inflammation, and pain in irritable bowel syndrome. Am. J. Physiol. Gastrointest. Liver Physiol. 2012, 303, G775–G785.
33. Matricon, J.; Meleine, M.; Gelot, A.; Piche, T.; Dapoigny, M.; Muller, E.; Ardid, D. Review article: Associations between immune activation, intestinal permeability and the irritable bowel syndrome. Aliment. Pharmacol. Ther. 2012, 36, 1009–1031.
34. Simrén, M.; Barbara, G.; Flint, H.J.; Spiegel, B.M.; Spiller, R.C.; Vanner, S.; Verdu, E.F.; Whorwell, P.J.; Zoetendal, E.G.; Rome Foundation Committee. Intestinal microbiota in functional bowel disorders: A Rome foundation report. Gut 2013, 62, 159–176.
35. Round, J.L.; Mazmanian, S.K. The gut microbiota shapes intestinal immune responses during health and disease. Nat. Rev. Immunol. 2009, 9, 313–323.
36. Ringel, Y.; Maharshak, N. Intestinal microbiota and immune function in the pathogenesis of irritable bowel syndrome. Am. J. Physiol. Gastrointest. Liver Physiol. 2013, 305, G529–G541.
37. Hughes, P.A.; Zola, H.; Penttila, I.A.; Blackshaw, L.A.; Andrews, J.M.; Krumbiegel, D. Immune activation in irritable bowel syndrome: Can neuroimmune interactions explain symptoms? Am. J. Gastroenterol. 2013, 108, 1066–1074.
38. Palego, L.; Betti, L.; Rossi, A.; Giannaccini, G. Tryptophan biochemistry: Structural, nutritional, metabolic, and medical aspects in humans. J. Amino Acids 2016, 2016, 8952520.
39. Murray, M.F. Insights into therapy: Tryptophan oxidation and HIV infection. Sci. Transl. Med. 2010, 2, 32ps23.
40. Alexaki, A.; Liu, Y.; Wigdahl, B. Cellular reservoirs of HIV-1 and their role in viral persistence. Curr. HIV Res. 2008, 6, 388–400.
41. Coleman, C.M.; Wu, L. HIV interactions with monocytes and dendritic cells: Viral latency and reservoirs. Retrovirology 2009, 6, 51.
42. Epelman, S.; Lavine, K.J.; Randolph, G.J. Origin and functions of tissue macrophages. Immunity 2014, 41, 21–35.
43. Distrutti, E.; O’Reilly, J.A.; McDonald, C.; Cipriani, S.; Renga, B.; Lynch, M.A.; Fiorucci, S. Modulation of intestinal microbiota by the probiotic VSL#3 resets brain gene expression and ameliorates the age-related deficit in LTP. PLoS ONE 2014, 9, e106503.
44. Vujkovic-Cvijin, I.; Swainson, L.A.; Chu, S.N.; Ortiz, A.M.; Santee, C.A.; Petriello, A.; Dunham, R.M.; Fadrosh, D.W.; Lin, D.L.; Faruqi, A.A.; et al. Gut-resident lactobacillus abundance associates with IDO1 inhibition and Th17 dynamics in SIV-infected macaques. Cell Rep. 2015, 13, 1589–1597.
45. Mardini, H.E.; Grigorian, A.Y. Probiotic mix VSL#3 is effective adjunctive therapy for mild to moderately active ulcerative colitis: A meta-analysis. Inflamm. Bowel. Dis. 2014, 20, 1562–1567.
46. Kumar, R.; Singh, J. The emerging therapy with probiotics in the management of inflammatory bowel disease: Current status. Int. J. Basic Clin. Pharmacol. 2013, 2, 360–367.
47. Scagnolari, C.; Monteleone, K.; Selvaggi, C.; Pierangeli, A.; D’Ettorre, G.; Mezzaroma, I.; Turriziani, O.; Gentile, M.; Vullo, V.; Antonelli, G. ISG15 expression correlates with HIV-1 viral load and with factors regulating T cell response. Immunobiology 2016, 221, 282–290.